Commensal and Probiotics-Host Interactions (ProbiHote)
Probihote
description
Our team focus is in the areas of a better knowledge of the crosstalk between host and resident and transiting microbiota in physiological and patho-physiological conditions. They should lead to an optimized use of commensal and probiotic bacteria in human and animal health. We also study the mechanisms involved in the complex crosstalk between the gut microbiota and the host in health, and its alterations leading to human diseases such as Inflammatory Bowel Diseases (IBD), Irritable Bowel Syndrome (IBS), Short bowel Syndrome (SBS).
Our team has acquired an international recognition and is considered as leader in the following scientific fields involving the crosstalk host-bacteria
- health-related effects of commensal and probiotic bacteria
- use of recombinant lactic acid bacteria to deliver molecules of health interest
- impact of microbiota on digestive physiology
Organization :
Fields of interest
LANGELLA
Philippe
Team/Group
Leader
Contact info
Address: INRA-Institut National de la Recherche Agronomique UMR 1319 MICALIS-Microbiologie de l'Alimentation au Service de la Santé humaine Domaine de Vilvert-Bât. 440 R-2City: Jouy-en-Josas, France
Postal code: 78352
Telephone: +33 1 34 65 20 70
Fax: +33 (0) 1 34 65 24 62
Email: philippe.langella@jouy.inra.fr
Website: https://www.micalis.fr/Institut-Micalis
Top Publications
- Martín R, Chain F, Miquel S, Natividad JM, Sokol H, Verdu EF, Langella P, Bermúdez-Humarán LG.
Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Hum Vaccin Immunother
Hum Vaccin Immunother. 2014 Apr 14;10(6).